Cancer patients struggle with shortage of vital digestive medication
- markdarrenwilkinso
- 6 days ago
- 2 min read
Ongoing Shortage of Digestive Drug Puts Pressure on Channel Islands' Healthcare Services
Pharmacists across the Channel Islands are grappling with an ongoing shortage of a critical digestive medication frequently prescribed to cancer patients and others with serious conditions.
The drug, Creon—a pancreatic enzyme replacement therapy (PERT)—has been in short supply since summer 2024, with UK pharmacists calling it one of the most severe medicine shortages in recent memory. While it does not treat cancer directly, Creon plays a vital role in helping individuals with pancreatic cancer, cystic fibrosis, and chronic pancreatitis digest food properly.
A spokesperson for Guernsey’s Prescribing Support Unit confirmed the persistent supply challenges, noting that the Department of Health in England issued a national patient safety alert in December 2024. "Local pharmacies have been working diligently to maintain supplies," the spokesperson said. "At times, this has been a significant challenge."
On average, around 70 PERT prescriptions are filled each month in Guernsey. Despite the ongoing disruptions, officials report no known cases of patients going without the drug—a fact attributed to the proactive efforts of community pharmacy teams.
In Jersey, health authorities are also feeling the strain. Kevin Smith, Acting Director of Pharmacy Services, acknowledged that the shortage is likely to persist for several months. To conserve supply, the island has implemented temporary measures such as issuing shorter prescription durations.
"Clinical and pharmacy teams are collaborating closely with hospital staff to identify appropriate alternative treatments where necessary," Smith added.
Dr. Elizabet Gomes Dos Santos, oncology consultant in Jersey, emphasized the importance of patient care amid the shortage. "Patient safety remains our top priority," she said. "We are dedicated to upholding high standards and ensuring patients continue to receive essential support during this challenging period."
